News & Updates

Tambotatug pelitecan (Tam-Peli), a novel B7-H3–targeting antibody–drug conjugate, delivers significant survival boost in relapsed small-cell lung cancer (SCLC) as compared with topotecan, according to the phase III TAISHAN-302 trial.

Results from the Italian RISP* trial presented at WCLC 2026 show improvement in smoking cessation rates following treatment with cytisine, a partial agonist of α4β2nicotinic acetylcholine receptors.

In the first-line treatment of patients with advanced HER2-mutant non-small cell lung cancer (NSCLC), trastuzumab deruxtecan (T-DXd) monotherapy confers a 6-month improvement in progression-free survival (PFS) compared with pembrolizumab plus chemotherapy, as shown in the phase III DESTINY-Lung04 trial.

Patients with chronic hepatitis B (CHB) infection who consume high levels of alcohol are at increased risk of hepatocellular carcinoma (HCC), as suggested in a retrospective study from China.

A report from Children’s Oncology Group (COG) AALL1731 study showed that paediatric patients with standard-risk (SR) B-cell acute lymphoblastic leukaemia (B-ALL) with undetectable minimal residual disease (MRD) at end of induction (EOI) by flow cytometry (FC) but not high-throughput sequencing (HTS) had inferior outcomes on chemotherapy alone, which were partially but not entirely mitigated by blinatumomab. In addition, outcomes of chemotherapy-only treatment among patients with MRD by HTS were not superior to those of patients with detectable MRD.

Some biomarkers of one-carbon metabolism are associated with toxicities induced by chemotherapy in patients with stage II‒III colorectal cancer (CRC), suggests a study.

Replacing two cycles of highly toxic, high-dose combination chemotherapy with two cycles of blinatumomab as first-line (1L) treatment significantly improves outcomes including 4-year event-free survival (EFS) and reduces adverse events (AEs) in paediatric patients with high-risk B-cell acute lymphoblastic leukaemia (B-ALL), results of the phase III AIEOP-BFM 2017 trial have shown.

New drug applications approved by US FDA as of 16-30 September 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Cytological analysis of voided urine and vaginal fluid has good accuracy for detecting endometrial cancer in women with postmenopausal bleeding, as shown in the DETECT trial.